Introduction
Specific inhibition of tumorigenic cells but not of benign cells is of central interest in tumor therapy. The growth of normal cells is characterized by the balanced action of proto-oncoproteins and tumor suppressor proteins. Mutation or modulation of the expression of protooncogenes or tumor suppressor genes may cause transformation. In this respect, the interferon regulatory factor (IRF-1) is an interesting candidate (for reviews see Taniguchi et al., 1997; Kro¨ger et al., 2002) . IRF-1 is a nuclear transcriptional activator. It is expressed constitutively at a very low level in almost every cell type. Its transcription is transiently induced by various cytokines and hormones. Typical inducers are interferons, TNFa, IL-1, IL-6, dsRNA and viruses. IRF-1 induces IFN-stimulated genes such as those encoding MHC class I (Hobart et al., 1996; Salkowski et al., 1996) , iNOS (Kamijo et al., 1994) and GBP (Briken et al., 1995) . IRF-1 is also necessary for the proper expression of IL-15 (Ogasawara et al., 1998) , p21 (Tanaka et al., 1996) and IFN-b (Matsuyama et al., 1993) . Studies with IRF-1 knockout cells demonstrate that IRF-1 is involved in the differentiation and function of NK cells (Ohteki et al., 1998; Ogasawara et al., 1998) in Th switching and DNA damage (Tanaka et al., 1996; Tamura et al., 1997a) . Moreover, IRF-1 shows tumor suppressor activity under certain conditions (Tanaka et al., 1994a (Tanaka et al., , 1996 and IRF-1 overexpression inhibits cell growth (Kirchhoff et al., 1993) . Embryonic fibroblasts deficient in IRF-1 genes become transformed by a single oncogene (c-Ha-ras). These cells do not undergo apoptosis upon c-Ha-ras oncogene expression and serum starvation, while wild-type cells harboring IRF-1 genes undergo programmed cell death (Tanaka et al., 1994b) . IRF-1 expression in tumor cells leads to activation of the adaptive immune system and to an immunological control of the implanted tumor cells in mice (Yim et al., 1997; Kro¨ger et al., 2001 ). Tcell-mediated immunity directed against respective tumor antigens from the primary inoculated cells results in a vaccination for wild-type tumors (Kro¨ger et al., 2001) .
Previously, the features of IRF-1-mediated growth inhibition of diverse tumorigenic cells were described . A fusion protein in which IRF-1 is fused to the hormone-binding domain of the human estrogen receptor (hER), thus rendering IRF-1 function dependent on b-estradiol activation was applied (Kirchhoff et al., 1993) . b-Estradiol treatment leads to a strong proliferation inhibition of various transformed cell lines expressing this fusion protein.
However, IRF-1 induces cell growth inhibition not only in oncogenically transformed cells, but also in nontransformed cells (Kirchhoff et al., 1993) . IRF-1 expression in NIH3T3 cells expressing the adenovirus proteins E1a and E1b in BC1 sarcoma cells, in MMV transformed C243 cells and in HER1-expressing cells showed that the extent of proliferation inhibition varies significantly. In cell lines overexpressing HER1 (the epidermal growth factor receptor (EGFR)) when activated by EGF active IRF-1 causes a nearly complete inhibition of metabolic activity. While EGFR signaling alone stimulates cell growth, IRF-1 activation alone reduces the cell growth rate. It was found that the simultaneous activation of EGFR and IRF-1 synergistically induces cell death. Crosstalk between the EGFstimulated STAT and MAPK pathways, as well as between phorbol ester activated PKC, p38K and MAPK pathways takes place, suggesting that MAPK signaling is of central importance in IRF-1-induced synergistic cell death . Other cell lines in which the MAPK pathway is constitutively activated also die by apoptosis (Schroeder et al., unpublished) .
During the examination of IRF-1 function in other cell lines, we could not detect apoptosis as a cause for the observed inhibition of the metabolic activity. However, we consistently saw a significant inhibition of the cellular metabolism upon IRF-1 activation and an inhibition of the oncogenic activity in vitro. In this study, we have examined the features of IRF-1 activity in NIH3T3 cells which were either left in a nononcogenic state or which were transfected with various oncogenes with respect to cell growth, soft-agar colony formation, cell cycle or tumor formation in vivo. We also examined the influence of IFN-b, which is secreted by these cells upon IRF-1 activation. Our data indicate that IRF-1 independent of IFN-b reverts all measured phenotypic properties induced by oncogenic transformation in vitro and in nude mice.
Results

IRF-1 inhibits cell growth of different transformed NIH3T3 cells
To investigate the growth-inhibitory effect of IRF-1 on transformed cells, we transfected the estradiol activatable IRF-1hER fusion protein into NIH3T3 cells in which single oncogenes of different classes as well as cooperating oncogenes were stably established before. Transfectant clones with comparable levels of IRF1hER expression were selected ( Figure 1a ). Cell growth of these clones was determined by measuring their Figure 1 IRF-1 inhibits cell growth of transformed cells. Cell lines overexpressing the indicated oncogenes were stably transfected with a construct encoding IRF-1hER. Cell clones with equal expression of IRF-1-hER were selected. Nontransfected NIH3T3 cells were used as a control. HER1 in NIH3T3 HER1 cells is constitutively expressed and was activated by 20 ng/ml EGF. (a) Western blot analysis of the IRF-1hER fusion protein. Lysates (50 mg of protein) from selected cell clones were subjected to SDS-PAGE and analysed using an antiestrogen receptor antibody (top panel). The arrow indicates the size of the fusion protein. Degradation products are detected as well. The membrane was stripped and reprobed with an antiactin antibody to control protein loading of the samples (bottom panel). (b) For determination of cell growth, IRF-1-hER expressing cells derived from the clones as described in (a) were seeded into microtiter plates and grown without (c) or with 1 mm b-estradiol (+E2). The metabolic activity of cultures was measured after 7 days of treatment. The metabolic activity of nontransfected cells was set as 100% (not shown)
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A Kröger et al metabolic activity 7 days after IRF-1 activation by bestradiol. As shown in Figure 1b all cell lines were sensitive to IRF-1 activity with respect to inhibition of the metabolic activity, but the extent of this inhibition varied significantly. The nontransformed NIH3T3 cell line showed a 30% inhibition. The HER2 transformed cell line showed an inhibition of the metabolic activity of 35%, whereas the cells transformed either by c-myc, Hras or c-myc plus H-ras showed an inhibition of 42 and 54%. The strongest inhibition of metabolic activity was seen in NIH3T3 cells expressing the active form of HER1 oncogene (98%). This strong effect, however, is mediated by the induction of apoptosis as previously shown . In contrast, the reduction of the metabolic activity in the other cell lines could not to be correlated with apoptosis. This was analysed by examination of subdiploid DNA and annexin staining (data not shown). Since no significant cell death by necrosis could be detected, the inhibition of metabolic activities in these cells is because of an inhibition of cell growth. As shown earlier, the corresponding cell lines that do not express the IRF1hER fusion protein did not react to b-estradiol treatment with growth inhibition (Kirchhoff et al., 1993 (Kirchhoff et al., , 1995 . Thus, IRF-1 inhibits the growth of the tested transformed NIH3T3 cells independent of the class of the expressed oncogene. This inhibition is slightly stronger than in nontransformed progeny cells. The extent of proliferation inhibition varies among these cell lines.
IRF-1hER activation reverts the transformed phenotype
A hallmark of oncogenically transformed cells is focus formation and growth in soft-agar. While normal NIH3T3 cells do not form soft-agar colonies, our panel of derivatives transfected with the oncogenes led to the formation of soft-agar colonies (Figure 2 ). To determine whether IRF-1 influences the transformed phenotype in these cells, we tested their ability to grow in soft-agar in the presence of activated IRF-1 (+b-estradiol).
In all cases, the activation of IRF-1 reduced the number of soft-agar clones by more than 70%. Since transformed cells that do not express IRF-1hER are not influenced in their soft-agar growth by b-estradiol, the hormone as such does not influence this property ( Figure 2 ). As shown earlier in HER1-transfected cells that are treated with EGF, IRF-1 activation eliminates the cells by apoptosis. For the other cell lines, the strong inhibition of colony formation (72-100%) cannot be explained by the observed cell growth inhibition (30-50%). In general, growth inhibition is not as drastic as the inhibition of soft-agar growth indicating that the two parameters do not correlate. The inhibition of this oncogenic property seems to be independent of the molecular nature of transformation, since it is seen with all cell lines examined in this study.
A striking example represents the cells expressing cmyc and c-Ha-ras. Proliferation is inhibited by IRF-1 to about 50%, but colony formation of this cell line is completely abolished. The strong inhibition of soft-agar growth in the cells expressing c-myc and c-Ha-ras looks like a complete reversal of the oncogenic phenotype by IRF-1 expression. To confirm this result, we constructed new NIH3T3 cells expressing c-myc, c-Ha-ras and IRF1hER, however, in a way that expression of the oncogenes is conditional. This allows one to investigate IRF-1 activity in nontransformed and transformed cells in the same cell line. The tet-off system (Gossen and Bujard, 1992 ) with a bidirectional promoter (Baron et al., 1995) was chosen and cell clones were isolated in which oncogene expression as judged by growth in softagar is completely reversible (Figure 3c , black bars). IRF-1-mediated cell growth inhibition of the nontransformed and the transformed cells is shown in Figure 3a . Inhibition in cells without oncogenes is less pronounced than that of cells expressing both oncogenes. The extent of proliferation inhibition of these cells is similar to the cells that were constitutively expressing these oncogenes (compare Figure 1b Thus, IRF-1 property specifically eliminates the oncogenic properties of the combined action from c-myc and c-Ha-ras.
IRF-1-mediated antiproliferative effects are independent of interferon effects IRF-1 overexpression induces IFN-b secretion (Harada et al., 1990; Kirchhoff et al., 1995a, b) . This was shown to occur in different cell lines from various species. It is because of a direct binding of IRF-1 to the IFN-b promoter together with NF-kB binding which is indirectly induced by IRF-1-mediated induction of the PKR gene, which in turn activates IkB phosphorylation . Interferons are well known as cytokines with proliferation inhibitory activity (Stark et al., 1998) . However, the inhibition strongly depends on the cell type. All NIH3T3 cells, independent of their oncogene expression, secreted IFN-b upon IRF-1 activation (data not shown). The above-described cell line expressing c-myc and c-Ha-ras conditionally and the IRF-hER fusion protein constitutively accumulated about 700 IU/ml of IFN in 24 h after b-estradiol treatment (Table 1) . Using neutralizing antibodies directed against IFN-b, we confirmed that the secreted IFN was exclusively IFN-b. We investigated whether the secreted IFN would be responsible for the observed cell growth inhibition. We first incubated the cells in the absence of b-estradiol with various concentrations of murine IFN-b. The metabolic activity was reduced by 25% at IFN concentrations from 200 to 1000 IU/ml (data not shown). In contrast, activation of IRF-1 leads to a much stronger reduction of the metabolic activity (by 44%) (Figure 3a) . We further inhibited the endogenously produced IFN-b after IRF-1 activation (Figure 4 ). This was done by the addition of a surplus of anti-IFN-b MAB to the culture. The results show that a titration of interferon does not affect IRF-1-mediated cell growth. Thus, IRF-1 induced an intrinsic growth inhibitory effect that is independent of the simultaneously secreted IFN-b.
Interferon secretion is not needed for reversion of the transformed phenotype
Interferons exhibit not only antiproliferative function, but are also described to interfere with tumorigenicity (Gresser, 1989) . Since IRF-1 activation efficiently inhibits cell growth in soft-agar, we examined whether IRF-1 -mediated IFN-b secretion might be involved. On the basis of the amount of secreted IFN from these cells (Table 1) , we calculated that the 10 3 cells in 50 ml of agar could create about 140 IU/ml in 10 days, assuming that no cell growth takes place and the IFN can freely diffuse. The first assumption is justified. Our microscopic examinations reveal no significant cell growth in the culture where IRF-1 is activated. However, a free diffusion cannot be guaranteed in soft-agar culture. Assuming that local concentrations accumulate 100-fold the concentration of local IFN would be 1400 IU/ml after the first day and 14.000 IU/ml after 10 days. We thus added IFN-b at concentrations of up to 20 000 IU/ ml to transformed cells (Àdox, + E2) at seeding in softagar. While the number of colonies was reduced at an IFN concentration of 4000 IU/ml to 80% and of 20 000 IU/ml to 20%, the activation of IRF-1 by bestradiol (+E2) led to a total (0%) inhibition of colony formation ( Figure 5 ). In another approach, the cells were seeded in the presence of IFN-b neutalizing antibodies. No reversion of IRF-1 inhibition was found (data not shown). This led us to conclude that the effect of IRF-1 activation on in vitro oncogenicity is not mediated by IFN-b.
IRF-1 reverts the oncogene-mediated cell cycle activation
The data shown in Figures 2 and 3b and c indicate that activation of IRF-1 reverts the oncogenic phenotype gained by the NIH3T3 cells through transformation with c-myc and c-Ha-ras. This phenomenon was specified by analysis of the cell cycle under different conditions. Cells in the nontransformed state (+dox-ycycline; -b-estradiol, Figure 6 , upper left) were indistinguishable from the w.t. NIH3T3 cells (data not 
IFN in the supernatant of 10 6 seeded cells was determined after 10 days of cultivation by measuring antiviral activity. (Figure 6 , left panel). All changes were characterized by a slight reduction of G2/M and a rise of S phase. This is also true for the cells in which IRF-1 was activated (+b-estradiol), although cell growth was inhibited to 70-80% as compared with the untreated culture. We have seen this effect in other cell types earlier (Kirchhoff et al., 1995b ; and data not shown). It was found that cell growth inhibition by IRF-1 activation leads to an extension of the cell cycle length without changing the proportion of cells in G1, S and G2-M. Upon activation of oncogene transcription for more than 3 days (Àdoxycycline) a significant increase of the S phase cell proportion and a reduced proportion of G1 phase cells indicated an increase in proliferating cells. (Figure 7a ). Tumor sizes of a 1500 mm 3 were reached at least 3 weeks later than in untreated animals. While the time of tumor onset varied among these animals, the kinetics of The delayed tumor formation in more than 50% of the animals suggests that IRF-1 activation might not be sufficient for tumor suppression in all cases. Alternatively, the expression or the activation capacity of IRF-1hER in tumor cells of the b-estradiol-treated animals might be reduced. To distinguish between both alternatives cells from tumors of b-estradioltreated or-untreated mice were isolated and cultivated. As expected, these cells formed soft-agar colonies in the absence of b-estradiol. However, the suppression of this property after b-estradiol treatment was only retained in the cells obtained from animals without b-estradiol treatment, whereas the cells from the delayed tumors (+b-estradiol) were not affected by IRF-1 activation (data not shown). The presence of the fusion protein in both cultures was compared to that from the inoculum (Figure 8a ). The data indicate that most (more than 90%) of the IRF-1hER protein expression is lost in cells from the delayed tumors. Accordingly, IRF-1 activation in these cells did not lead to a significant growth inhibition of the cells if compared to those from untreated animals or from the inocculum (Figure 8b) . We conclude that the tumor formation in b-estradiol-treated animals is because of a loss of expression of the IRF-1hER fusion protein and that IRF-1 activity prevents tumor formation, suggesting that cells can only escape from IRF-1-mediated tumor suppression by inactivating its expression. 
Discussion
With this work, we have tried to systematically examine the effects of IRF-1 expression on transformation of NIH3T3 cells initiated by different oncogenes. Earlier work suggested IRF-1 expression suppresses transformation properties induced by c-myc, fosB, IRF-2 and EGFR (Harada et al., 1993; Tanaka et al., 1994a, b; Futaki et al., 1996; , however, in various cellular backgrounds. Our results demonstrate that the activity of IRF-1 on transformation is not restricted to certain classes of oncogenes and is also mediated in cells expressing cooperative oncogenes. This indicates a general antitumor effect of IRF-1. The mechanism of transformation inhibition by IRF-1 is not well understood. IRF-1 exerts its effects by DNA binding and transactivation (Kirchhoff et al., 1993) . However, activities like those induced by IL-17 or E6/E7 abolish or reduce its DNA binding and thus decrease the expression of IRF-1-induced genes (Park et al., 2000; Andoh et al., 2002) . IRF-1 induces the transcription of a number of genes that exert growth inhibitory effects. Among them are Lysyloxidase (Tan et al., 1996) , PKR (Kirchhoff et al., 1995a, b; Tanaka and Samuel, 1994) , 2 0 -5 0 OASE (Benech et al., 1987) , Indoleamine 2,3-dioxigenase (Takikawa et al., 1988) and Angiotensin type II receptor (Horiuchi et al., 1997) . Furthermore, the promoter regions of certain caspase genes like ICE contain ISRE-like sequences (Chin et al., 1997; Tamura et al., 1997a ,b) . These genes have been shown to be targets of IRF-1 action. Further, IRF-1 plays a role in apoptosis in response to DNA damage and during serum starvation (Tanaka et al., 1994b; Tamura et al., 1995) . In many established cell lines of fibroblastoid and epithelial origin, IRF-1 leads to growth arrest with no typical signs of apoptosis .
The data presented in the results section show several phenotypes elicited by the IRF-1 activity on mouse fibroblasts transformed with well-known oncogenes. The observed inhibition of metabolic activity was measured in all tested oncogenic cell lines and was usually stronger than in the respective nontransformed progenitor cells. Since with exception of HER1-transformed cells the other cells neither showed significant apoptosis nor necrosis, we regard this effect as an inhibition of cell growth. Under certain conditions IRF-1 expression induces apoptosis. Nguyen et al. (1997) have shown that the expression of a fusion protein of IRF-1 and the strong transactivation domain of p65 (RelA) in NIH3T3 cells leads to growth inhibition, however, apoptosis is initiated under serum starvation. Further, IRF-1 activation in cells expressing the activated HER1 protein underwent apoptosis (Chin et al., 1997; . Current work indicates that the activation of the MAPK pathway is essential for this interference with IRF-1 activity. However, in cells expressing c-Ha-ras or HER2 the same pathway is activated but apoptosis is not seen. This suggests that either the MAPK pathway activation is not sufficient or that other signalling activities from these oncogenes block the interference with IRF-1, for example, by inhibiting the apoptotic death cascade.
Transformed cells usually have a high portion of the culture in the S and G2 phases of the cell cycle. This is also true for the ras+myc-transformed cells (Figure 6 ). Activation of IRF-1 in these transformed cells leads to an extention of the G1 phase, resulting in a cell cycle distribution that is indistinguishable from that of nontransformed cells. Interestingly, the activity of IRF-1 in the nontransformed cells does not alter the cell cycle distribution, although proliferation of this culture is diminished. This is because of a slowdown of the overall passage through the cell cycle. Thus, the expression of IRF-1 in transformed cells has a different effect on the cell cycle as in nontransformed cells. An accumulation in G1 as induced by IRF-1 in the transformed cells could be induced by a higher expression of p21 (WAF1, CIP1), a CDK inhibitor. It has been reported that IRF-1 with p53 induces p21 leading to a G1 arrest (Tanaka et al., 1996) . In addition, Stat1 has Expression of IRF-1 A Kröger et al been shown to activate transcription of p21 by IFN-g or EGF, resulting in cell growth inhibition (Chin et al., 1996) , IRF-1 or an IRF-1-induced gene regulates STAT1 expression at the transcriptional level (Nguyen et al., 1997) . However, analysis of p21 protein expression showed no alteration after IRF-1 activation in the nontransformed and in ras+c-myc-transformed cells (data not shown). Therefore, we do not consider a regulatory involvement of this cell cycle suppressor in the action of IRF-1. An important phenotype elicited by IRF-1 is the suppression of transformed cell growth as determined in soft-agar and nude mice. The strong suppression of this activity appears as if oncogene expression is eliminated. However, this is not the case. Control experiments with ras+myc-transformed cells show identical levels of both oncoproteins in cells before and after IRF-1 activation (data not shown). We assume that this is also true for the cells harboring the other oncogenes since these are transcribed from the same promoter.
From the multiple individual activities that each of the used oncogenes elicit, a few are shared by all of them. The transforming phenotype with respect to cell cycle acceleration, soft-agar growth and in vivo tumor growth is one of those common activities. Since IRF-1 expression counteracts this phenotype in all tested oncogenic transformants, one explanation is that a common molecular target downstream from all explored oncogenes essential for the transforming phenotype is responsible. Alternatively, IRF-1 induces activities that act to suppress different events, including those which are provoked by the oncogenes. The induction of IFN-b by IRF-1 and its broad spectrum of activities could be an example for the latter alternative. Type I interferons are well known to exert various direct antitumor effects and indirect immune stimulatory activities (Lengyel, 1982; Stark et al., 1998; Qin et al., 2001) . This is the reason why an involvement of IFN-b was investigated. From our results we have concluded that secreted IFN-b is not responsible. However, we cannot completely exclude that IFN-b is partially contributing to the IRF-1-mediated effects. IFN-b might bind to its receptor before or immediately after it has been released from the cells. A final examination can only be done by repeating the experiments in cell lines derived from IFN-b À/À or IFNIR À/À mice. The first alternative, a common molecular target, was also considered. In theory, a large number of molecular targets have to be considered. We have tested only two potential candidates, namely the involvement of p21 and lysyloxidase. As discussed above p21 is not involved. Lysyloxidase plays a key role in the activity of extracellular matrix protein modification and thereby in transforming activities. This was convincingly shown by Friedman and colleagues (Contente et al., 1990) . In c-Ha-ras-transformed NIH3T3 cells the expression of lysyloxidase is drastically decreased. Long-term IFN treatment reverts the transformed phenotype of these cells and returned lysyloxidase expression to normal levels (Contente et al., 1990; Kenyon et al., 1991) . The transformed phenotype of ras-expressing cells could be successfully suppressed by overexpression of lysyloxidase mRNA (Kenyon et al., 1991) . Finally, lysyloxidase mRNA expression is induced upon IRF-1 activation (Tan et al., 1996) . Thus, lysyloxidase is a potential downstream mediator of IRF-1's tumor suppressor activity. The involvement of lysyloxidase in our conditional transformation/reversion system was examined by lysyloxidase overexpression in the transformed cells controlled by bicistronic coexpression with eGFP (data not shown). However, the ras+myc-induced phenotype with respect to soft-agar growth was not altered. Since mRNA levels of lysyloxidase in the cultivation of these cells under different conditions were constant, we believe that the involvement of lysyloxidase in IRF-1-mediated transformation suppression is not given.
One important finding of our study is the differential tumor growth in nude mice. b-Estradiol treatment protects 40% of the mice from tumor growth. These mice that developed tumors were characterized by a significantly delayed onset of tumor growth. Isolated cells from these tumors showed a nearly complete loss of IRF-1 expression, suggesting that this loss enables tumor growth. In immune-competent mice, IRF-1 activation protects the animals from tumor development. Subsequent injection of w.t. tumor cells leads to a T-cell-mediated rejection (Kro¨ger et al., 2001) .
The results from this paper demonstrate that IRF-1 induces a direct effect in addition to the earlier observed indirect antitumor effects. The direct (intrinsic) effect is characterized by the inhibition of cellular proliferation and oncogenic transformation. The indirect effect involves the stimulation of the immune response against tumor-specific antigens. A potential function of the direct effect might be important for the overall antitumor activity of IRF-1: activity of IRF-1 in tumor cells arrests them in proliferation and allows the activation of the adaptive immune system before formation of large solid tumor tissue is possible.
Materials and methods
Establishment and induction of recombinant mammalian cells
NIH3T3-based cell lines stably expressing the oncogenes c-myc, c-Ha-ras, HER1, HER2 or c-myc plus c-Ha-ras were generated and selected by soft-agar growth. These cells were stably cotransfected with an expression construct encoding IRF-1hER (Kirchhoff et al., 1993) , and a hygromycin (Blochlinger and Diggelmann, 1984) or a neomycin resistance conferring plasmid (Colbe`re-Garapin et al., 1981) . A NIH3T3 cell line expressing c-myc and c-Ha-ras under the control of the tetracyline regulatable promoter (tTA) was created. These cells were supertransfected with the expression vector encoding IRF-1hER together with the neomycin resistance expression construct. Results from individual cell clones were representative for the respective pools. These clones were taken for the experiments shown here. All cells were grown in DME plus 10% of estrogen-free fetal calf serum, antibiotics, glutamine, the respective selective drugs and doxycycline (2 mg/ml) as indicated. Doxycyline-containing media were renewed every 48 h. To activate IRF-1 in the IRF-1hER fusion protein the medium was adjusted with b-estradiol to the indicated concentration. For activation of HER1 the medium was adjusted to 20 ng/ml EGF (Sigma). For expression of tTA regulated cDNAs, the cells were washed several times and cultured without doxycycline (Kirchhoff et al., 1995a, b) . DNA was transfected using calcium phosphate coprecipitation (Graham and van der Eb, 1973) .
Plasmid constructions
Constructions were carried out by standard procedures (Sambrook et al., 1989) . The constitutive expression vector for IRF-1-hER was described earlier (Kirchhoff et al., 1993) . Plasmids expressing HER1 and HER2 have been described previously Baasner et al., 1996) . Plasmids encoding c-myc and c-Ha-ras were kindly provided by B Lu¨scher and M Ahmadin. The tTA gene was expressed under the control of the tTA-promoter (pRBTtTA) resulting in autoregulatable gene expression (Unsinger et al., 2001) .
For doxycyline regulatable oncogene expression a bicistronic plasmid was constructed. The c-myc gene was PCR amplified and inserted into pBTVBC-1 (Kwissa et al., 2000) via EcoRI/HindIII resulting in pBTmyc. For bicistronic oncogene expression c-Ha-ras was PCR amplified and inserted by NotI 3 0 of the IRES element of pBTmyc. For selection a hygromycin-resistant gene was inserted as a PmeI fragment 5 0 of the bidirectional tTA promoter.
Measurement of cell growth
For determination of cell growth 2 Â 10 3 cells/well were seeded into microtiter plates and serial dilutions (1 : 1) were performed allowing several independent measurement points. Cells were treated with the indicated concentration of b-estradiol. Cell growth was determined using the WST kit (Roche Diagnostics, Mannheim, Germany) following the manufacturer's instructions. Mean values of triplicates were plotted.
Soft-agar colony formation
Anchorage-independent growth capability was determined by assessing the colony-formation efficiency of cells suspended in soft-agar. Cells (1 Â 10 3 ) were seeded in 50 ml of 0.3% overlay agar in microtiter plates coated with 50 ml of 0.6% underlay agar. The induction medium was added to the top (50 ml/well). Colonies were counted 2 weeks after plating. Mean values of triplicates were plotted.
IFN-test
The IFN concentration in the cell culture supernatants was determined by an antiviral assay using mouse L929 cells (Dinter and Hauser et al., 1987) . To confirm the specificity of the antiviral activity, a neutralizing monoclonal antibody directed against mouse IFN-b was added to the supernatant before addition to the test cells.
Western blotting
Cells were lysed in buffer containing 250 mm Tris, 0.5% Triton X-100, and 0.1 m PMSF. Immunoblots derived from whole cell extracts after separation on 10% SDS-PAGE and transfer to nylon membranes were probed with antibodies directed against the hormone binding domain of the human estrogen receptor (HC-30, Santa Crutz Biotechnology, USA) or actin (Ab-1, Oncogene, USA) and visualized by ECL (Amersham, Arlington Heights, IL, USA) according to the manufacturer's specifications.
Cell cycle analysis
Cells in which transfected oncogene transcription was active or inactive were plated in 100-mm dishes and treated after reaching 70% confluence. Both floating cells in the medium and cells attached to the plate were collected. After washing twice with phosphate-buffered saline, cells were fixed with 80% ice-cold methanol. The fixed cells were resuspended in 1 ml PBS containing 50 mg/ml of each RNase A and propidium iodide (mg/ml). Stained cells were analysed for relative DNA content by a FACScan analyser (Becton-Dickinson, Heidelberg, Germany). The percentage of cells residing in the sub-G1, G0/G1, S and G2/M fractions was determined using the 'Mod Fit' program.
Tumor growth in nude mice
Male 6-8-week-old NMRI nude mice (Harlan Winkelmann, Borchen, Germany) were used. Mice were divided into four experimental groups, 10 mice for each group. 1 Â 10 6 NIH3T3 cells in 0.2 ml PBS cells were injected subcutaneously into the flanks of the mice. After cell inoculation animals of groups 2 and 4 were treated with 1.5 mg of b-estradiol every 2 days i.p. and animals of groups 1 and 2 were treated with doxycyline supplied in the drinking water (40 mg/ml). Tumor volumes were measured and recorded three times a week using calipers. Data are presented as mean value of the tumor volume.
Reisolation of tumor cells
Tumors were isolated from mice and washed twice with phosphate-buffered saline. The tumors were cut into small pieces and homogenized. The tissue pieces were washed twice with phosphate-buffered saline and digested for 15 min with trypsin/EDTA. Cells and tissue pieces were cultivated in DME plus 10% of estrogen-free calf serum, antibiotics and glutamine. At 24 h after seeding the tissue pieces were removed and cells were cultivated up to confluency. Abbreviations EGFR, epidermal growth factor receptor; HER, hormonebinding domain of the human estrogen receptor; ISRE, interferon-stimulated recognition element; IFN-b, interferon beta; IRF-1, interferon regulatory factor 1; STAT, signal transducers and activators of transcription; GAS, gammainterferon activated sequence; E2, b-estradiol; Dox, doxycycline; MAB, monoclonal antibody; w.t., wild type.
